Aksys

Aksys granted continued listing by NASDAQ panel

Published in Lab Business Week, November 12th, 2006

Aksys, Ltd., (AKSY) a developer of dialysis systems, announced that the NASDAQ Listing Qualifications Panel has granted the company's request for continued listing on The NASDAQ Capital Market, subject to certain conditions.

The listing exception was granted based upon the company's plan to achieve compliance with NASDAQ's $35 million market value of listed securities requirement, as set forth in NASDAQ Marketplace Rule 4310(c)(2)(B).

As part of the plan of compliance, the company's largest stockholder, Durus Life Sciences Master Fund, Ltd., has indicated its willingness to convert shares of Series B preferred stock of the company into shares of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Business Week

Source: Lab Business Week (2006-11-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry